B cell malignancies
Clinical trials for B cell malignancies explained in plain language.
Never miss a new study
Get alerted when new B cell malignancies trials appear
Sign up with your email to follow new studies for B cell malignancies, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New antibody drug targets Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests an experimental drug called AZD5492 in people with B-cell cancers (like lymphoma or leukemia) that have come back or not responded to at least two prior treatments. The drug works by helping the body's T cells attack cancer cells. The trial will check safety, sid…
Matched conditions: B CELL MALIGNANCIES
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug HRS-1635 enters early human testing for hard-to-treat blood cancers
Disease control Recruiting nowThis early-phase study tests the safety and tolerability of a new drug called HRS-1635 in 180 adults with B-cell blood cancers that have come back or not responded to treatment. Researchers will find the best dose and watch for side effects. The goal is to control the disease, no…
Matched conditions: B CELL MALIGNANCIES
Phase 1 • Sponsor: Chengdu Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug duo aims to deepen leukemia remission
Disease control Recruiting nowThis study tests whether adding emavusertib to a standard targeted therapy (zanubrutinib) can improve outcomes for people with chronic lymphocytic leukemia (CLL) and other B-cell cancers. About 108 adults with CLL who have already received some treatment will take both drugs. The…
Matched conditions: B CELL MALIGNANCIES
Phase 2 • Sponsor: Curis, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
MRNA cancer therapy takes on blood tumors
Disease control Recruiting nowThis early-phase trial is testing an experimental mRNA-based drug that turns the body's own cells into cancer fighters. The drug targets CD19, a protein found on certain blood cancer cells. Researchers will enroll 47 adults with B-cell lymphoma or leukemia who have run out of sta…
Matched conditions: B CELL MALIGNANCIES
Early phase 1 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New CAR T-Cell therapy targets tough blood cancers
Disease control Recruiting nowThis study tests a new treatment called SHB-04-CD22, which uses a patient's own immune cells (T-cells) engineered to find and attack cancer cells that have a protein called CD22. It is for children and adults (ages 1-80) with B-cell cancers that have come back or not responded to…
Matched conditions: B CELL MALIGNANCIES
Phase 1/2 • Sponsor: Sheba Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC